The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Post-Operative Cataract Surgery Inflammation Treatment Market Progress Between 2026 And 2030?
The post-operative cataract surgery inflammation treatment market size has shown robust growth recently. It is projected to expand from $4.78 billion in 2025 to $5.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. The historical period’s expansion can be attributed to several factors including an increase in cataract surgery volumes, greater availability of ophthalmic anti-inflammatory drugs, the proliferation of outpatient surgical centers, advancements in surgical techniques, and a burgeoning aging population.
The post-operative cataract surgery inflammation treatment market is poised for significant expansion in the upcoming years. This market is projected to reach $6.78 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. The anticipated growth over the forecast period can be attributed to several factors, including an escalating demand for advanced ophthalmic formulations, an increasing focus on mitigating post-operative complications, the wider adoption of minimally invasive eye surgeries, rising investments in ophthalmology research, and the growing implementation of patient-specific treatment regimens. Prominent trends within this forecast period are expected to involve the increased application of combination anti-inflammatory therapies, a rising acceptance of ophthalmic NSAIDs, a heightened emphasis on achieving faster post-surgical recovery, the expansion of hospital-based ophthalmic care protocols, and an intensified focus on preventing post-surgical complications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21260&type=smp
Which Key Factors Are Driving The Post-Operative Cataract Surgery Inflammation Treatment Market Growth?
An increase in traumatic injuries is projected to drive the expansion of the post-operative cataract surgery inflammation treatment market in the foreseeable future. These injuries involve abrupt physical harm resulting from external impacts, including accidents, tumbles, acts of violence, or athletic collisions, and can vary from minor cuts to serious fractures, burns, brain trauma, and spinal impairment. The surge in traumatic injuries stems from various factors, including a greater number of road traffic accidents, occupational risks, sports-related mishaps, acts of violence, natural calamities, and elderly demographics susceptible to falls. Treatment for post-operative cataract surgery inflammation aids in managing traumatic injuries through decreasing eye inflammation, alleviating discomfort, and averting issues that might hinder visual recuperation. As an illustration, in October 2024, data from Insideworldfootball, a UK-based online news service, indicated that sports injuries totaled 4,123 throughout the 2023-24 season, representing a 4% rise when contrasted with the 2022-23 period. Consequently, the escalating occurrence of traumatic injuries is fueling the expansion of the post-operative cataract surgery inflammation treatments market.
Which Segment Types Are Examined In The Post-Operative Cataract Surgery Inflammation Treatment Market Segment Study?
The post-operative cataract surgery inflammation treatment market covered in this report is segmented –
1) By Drug Class: Bromfenac, Indomethacin, Diclofenac, Flurbiprofen, Nepafenac
2) By Route of Administration: Topical Ophthalmic, Intracameral And Ophthalmic Use
3) By Distribution Channel: Hospital pharmacy, Online Pharmacy, Retail pharmacy
Subsegments:
1) By Bromfenac: Bromfenac Ophthalmic Solution 0.07%, Bromfenac Ophthalmic Solution 0.09%, Combination Therapies With Bromfenac
2) By Indomethacin: Indomethacin Ophthalmic Solution 0.1%, Indomethacin Ophthalmic NSAID Formulations, Ophthalmic Anti-Inflammatory Solutions
3) By Diclofenac: Diclofenac Ophthalmic Solution 0.1%, Diclofenac Ophthalmic Drops, Ophthalmic NSAID Preparations
4) By Flurbiprofen: Flurbiprofen Ophthalmic Solution 0.03%, Adjunctive Use In Ocular Surgery, Combination Therapies With Flurbiprofen
5) By Nepafenac: Nepafenac Ophthalmic Suspension 0.1%, Nepafenac Ophthalmic Suspension 0.3%
Which Trends Are Guiding The Direction Of The Post-Operative Cataract Surgery Inflammation Treatment Market?
Leading companies in the post-operative cataract surgery inflammation treatment market are prioritizing the creation of innovative therapies, such as postoperative ocular analgesics, to bolster the reduction of pain and inflammation subsequent to ocular surgery. Postoperative ocular analgesics are therapeutic agents specifically designed to relieve pain and diminish inflammation in the eye following surgical procedures, thereby enhancing patient comfort and supporting favorable recovery outcomes. For example, in March 2024, Formosa Pharmaceuticals, a Taiwan-based pharmaceutical company, in partnership with AimMax Therapeutics, a US-based biotechnology company, obtained FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the management of post-operative pain and inflammation after ocular surgery. APP13007 stands as the first ophthalmic clobetasol propionate product approved by the FDA and signifies the introduction of the first new ophthalmic steroid to the market in over 15 years, providing a fresh option to address post-operative ocular inflammation and improve patient recuperation.
Which Players Are Part Of The Competitive Landscape Of The Post-Operative Cataract Surgery Inflammation Treatment Market?
Major companies operating in the post-operative cataract surgery inflammation treatment market are Alcon Inc, Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Merck & Co. Inc., Sun Pharmaceutical Industries Limited, EyePoint Pharmaceuticals Inc, Ocular Therapeutix Inc., Oculis Holding AG, Senju Pharmaceutical Co. Ltd., Nicox S.A., Formosa Pharmaceuticals Inc, Eyenovia Inc., Surface Ophthalmics Inc., ImprimisRx LLC, NTC Srl, VivaVision Biotech Inc., Bio-Tissue Inc., Mallinckrodt plc
Get The Full Post-Operative Cataract Surgery Inflammation Treatment Market Report:
Where Is The Post-Operative Cataract Surgery Inflammation Treatment Market Primarily Concentrated By Region?
North America was the largest region in the post-operative cataract surgery inflammation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative cataract surgery inflammation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Post-Operative Cataract Surgery Inflammation Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Post-Operative Cataract Surgery Inflammation Treatment Market 2026, By The Business Research Company
Hospice Care Market Report 2026
https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report
Acute Pancreatitis Market Report
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Intraoperative Imaging Market Report
https://www.thebusinessresearchcompany.com/report/intraoperative-imaging-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model